INTRODUCTION
Since the world's first successful heart transplantation was performed by Dr. Christiaan Barnard in 1967, it has come to be regarded as a standard treatment for end-stage heart failure. The first heart transplantation was performed successfully in Korea in 1992 [1] , and today, this procedure has become a widely accepted surgical option [2, 3] . The long-term results of heart transplantation in Korea are comparable with the results reported by the International Society of Heart and Lung Transplantation (ISHLT) [4, 5] . Among them, the bicaval technique is known to be associated with a decreased incidence of atrial arrhythmias and reduced need for pacemaker implantation because of the preservation of normal atrial geometry and sinus function [6, 7] . Since January 1999, we have employed the bicaval technique instead of the standard biatrial technique [4] . Although both these techniques have shown excellent long-term outcomes as previously reported, few studies have evaluated their early postoperative outcomes, including early complications and mortality. Such postoperative outcomes need to be studied further as they are the primary areas of interest for cardiac surgeons.
Therefore, we reviewed the early postoperative complications and mortality in adult recipients who underwent heart transplantations at the Asan Medical Center, using the bicaval technique. We are presenting our experience with early postoperative complications and their management, and the analysis of early mortality.
METHODS
A retrospective chart review was carried out on all patients who underwent orthotopic heart transplantation using the bicaval technique between January 1999 and December 2011.
A total of 286 patients underwent orthotopic heart transplantation, and of these, 247 patients were 17 years or older.
Among them, patients undergoing multi-organ transplantations were excluded: four patients with heart-lung transplantations and four patients with heart-kidney transplantations. Finally, 239 patients were enrolled in this study, comprising the current study population. Data were extracted from the prospectively registered database of Asan Medical Center, and supplemental information was obtained by reviewing the relevant medical records. The collected variables were basic demographic characteristics, preoperative diagnosis and laboratory data, preoperative need for inotropic support, preoperative intensive care unit (ICU) stay, preoperative mechanical circulatory support (MCS), total length of ICU and hospital stay, and postoperative complications. Postoperative complications included early graft failure, cerebrovascular accident (CVA), bleeding requiring re-exploration, renal failure requiring renal replacement therapy, low cardiac output syndrome requiring MCS, pericardial effusion, and inguinal lymphocele. This study was approved by the institutional ethics committee/review board at the Asan Medical Center (no. S2012-2199-0001), which waived the requirement for informed consent because of the retrospective nature of this study.
1) Operative technique
During the harvest, the heart was procured using cardioplegia with histidine-tryptophan-ketoglutarate solution (Custodiol HTK; Essential Pharmaceuticals, Newtown, PA, USA) injected through the aortic root cannula, with venting through the inferior vena cava (IVC) and the right upper pulmonary vein. A heart allograft is usually flushed with 2 L of Custodiol HTK solution and preserved with the same solution. In the case when the cold ischemic time ＞120 minutes, 1 L of Custodiol HTK solution was infused again into the heart allograft before anastomosis in some of the cases.
All recipients were prepared in a manner similar to that in the case of other open heart surgeries. Standard median sternotomy was performed, and the preparation for cardiopulmonary bypass (CPB) included aortic and bicaval cannulations.
Efforts were made to cannulate the aorta and both the superior and IVC as distally as possible. After the initiation of CPB, recipient cardiectomy was performed so that it could be completed simultaneously with the arrival of the donor heart. The bicaval technique sequenced the left atrial (LA) anastomosis first, usually followed by the IVC, pulmonary artery (PA), aorta, and superior vena cava (SVC) anastomosis.
Otherwise, anastomosis was performed in the sequence of LA, PA, aorta, IVC, and SVC. After the completion of anastomosis, 500 mg of solumedrol was administered intravenously, followed by the declamping of the aorta. In situations in which there were concerns regarding the prolonged ischemic time, aortic anastomosis was performed with the subsequent declamping of the aorta before the rest of the anastomosis was completed. After the completion of anastomosis, standard deairing maneuvers were performed, and the reperfusion of the implanted heart was begun. The entire procedure of anastomosis was performed under hypothermia using ice slush. After the patient was weaned off CPB, the usual pericardial, mediastinal, and pleural chest tubes and a peri- 
2) Postoperative management and immunosuppression
Prior to June 1999, the immunosuppression protocol consisted of induction with cyclosporine, azathioprine, and methylprednisolone [4] . Thereafter, all patients received anti-interleukin-2 receptor monoclonal antibody (basiliximab) preoperatively at the day of surgery, and started again on postoperative day 2. Intraoperatively, all patients received a bolus of methylprednisolone (500 mg), with tapering doses over months. Mycophenolate mofetil (CellCept; Roche Laboratories, Nutley, NJ, USA) was routinely started immediately after surgery, once the patient was extubated. Tacrolimus was usually given on postoperative day 2 once the creatinine level stabilized.
Once the patient was transferred to the ICU after surgery, the patient was given postoperative care in a manner similar to that in the case of other open heart surgery cases. After the patient was cleared off of mediastinal bleeding or neurologic dysfunction, he/she was weaned off mechanical ventilation and was usually extubated within 24 hours of surgery.
We tried to maintain adequate vital signs: the target systolic blood pressure and heart rate was 110 to 130 mmHg and 90 to 110 beats/min, respectively. Dopamine was the first choice of inotropes for maintaining adequate blood pressure, and the target heart rate was maintained using dobutamine and/or isoproterenol as appropriate. Further, we tried to maintain the urine output at least 100 mL/hr during the first 24 hours.
When the systolic pulmonary blood pressure was greater than 40 mmHg, iloprost (Ventavis; Bayer Schering Pharma, Berlin, Germany) inhalation was administered every 4 to 6 hours.
3) Follow-up
All patients underwent endomyocardial biopsy for the monitoring of acute rejection. Biopsies were taken on a regular basis for a two-year period after surgery, as previously reported [4] . A single expert cardiologist was involved in immediate postoperative care and long-term medical management at our institution. After the patients were discharged from the hospital, clinical follow-ups were performed during outpatient clinic visits. Follow-up was 100% complete with a mean follow-up duration of 58.4±43.6 months.
4) Statistical analysis
Categorical variables were presented as frequencies and percentages, and continuous variables as mean±standard deviation. Differences in baseline characteristics between the patient groups, categorized on the basis of the presence of complications, were compared using the Student t-test or 
RESULTS

1) Baseline characteristics
Of the 239 patients considered, 171 (71.5%) were male.
Further, the mean age at the time of transplantation was 45.1±12.5 years. Thirty-seven patients (15.5%) had undergone previous cardiac operations. Table 1 summarizes the baseline characteristics of all of the patients. The most common diagnosis among recipients was dilated cardiomyopathy (67.8%), followed by ischemic cardiomyopathy (13.4%) and hypertrophic cardiomyopathy (5.4%). Preoperative inotropic and mechanical support was provided to 114 patients (47.7%) and 7 patients (2.9%), respectively. Meanwhile, the mean age of the cardiac donors was 31.9±10.3 years, and 190 of these donors (79.5%) were male.
2) Early postoperative outcomes
There were three (1.3%) early deaths. Table 2 Values are presented as number (%) or mean±standard deviation. CRRT, continuous renal replacement therapy; CVA, cerebrovascular accident; TIA, transient ischemic attack. in 9 patients (3.8%), two of whom were already diagnosed with chronic renal failure preoperatively. One of them died of septic shock (patient 1 in Table 3) Table 3 ). Two patients were found to develop cerebral infarction on postoperative day 2 and are currently being followed up by neurologists in Asan Medical Center.
Sternal wound infection occurred in five patients (2.0%), and all of these patients underwent sternal wound revisions.
Among them, one patient had delayed wound infection one month after surgery. There was no case of recurrence after sternal wound revision.
Four patients (1.7%) and two patients (0.8%) required ECMO and intra-aortic balloon pump (IABP) support, respectively, due to low cardiac output or primary graft failure postoperatively. Of the four patients who were on postoperative ECMO support, one patient died of intracerebral hemorrhage as described previously (patient 2 in Table 3 ). This study demonstrated that the early mortality was excellent [8] , compared with that reported by other centers [9] [10] [11] . Due to the low incidence of early mortality, we were not able to identify the statistically significant risk factors for mortality. However, notably, two patients had preoperative hepatic dysfunction, which is compatible with previous studies suggesting an association between poor clinical outcomes and preoperative hepatic dysfunction [12] . The leading cause of early mortality was septic shock, followed by intracerebral hemorrhage, owing to anticoagulation during ECMO support.
In contrast to the 30-day mortality reported by ISHLT, in which primary graft failure is the leading cause of death [5] , graft failure was not listed as a cause of death in our study.
Other postoperative complications, including mediastinal bleeding, renal failure, early graft failure, CVA, and sternal wound infection reported in our study, could be compared favorably with those reported in other studies across the world [13] [14] [15] [16] [17] [18] . These complications could be adequately managed with either a surgical or medical modality. The presence of complications did not make a difference in the length of ICU and hospital stay in a majority of cases; patients with renal failure, arrhythmia, and ECMO insertion had a longer ICU stay, and patients with mediastinal bleeding had a longer hospital stay.
Our study recognized that the role of ECMO support has emerged as a preoperative bridge-to-transplantation as well as a postoperative bridge-to-recovery. Out of seven patients who received preoperative ECMO support and were bridged to transplantation, no one had postoperative mortality, and all of them had successful recovery after transplantation. Only one case of early mortality was reported in the postoperative ECMO group (patient 2 in Table 3 ); the remaining three patients were successfully bridged to recovery. The successful outcome of using ECMO as a preoperative bridge-to-transplantation and postoperative bridge-to-recovery indicates that ECMO support can be a viable option for managing preoperative end-stage heart failure patients and improving survival, particularly when compared with the general outcomes of ECMO support after major cardiac surgery. In addition, given the situation in Korea where ventricular assist device implantation is not generalized for patients with a failing heart [19] and ECMO support may be the only alternative option, the number of patients on the waiting list who may need preoperative ECMO support is expected to increase over time.
Our study showed that ECG-documented arrhythmias and pericardial effusion revealed by echocardiography were frequently observed after heart transplantation. RBBB was the most commonly documented arrhythmia, but none of the patients with RBBB showed hemodynamic instability that required pacemaker insertion. It appears that RBBB after heart transplantation does not have clinically significant implications; however, this needs to be further verified. This study has several limitations. First, it is a retrospective and non-randomized study with observational data. Therefore, the results might be affected by unmeasured confounders.
Second, this study incorporates the surgical outcomes of a thirteen-year period, performed by various surgeons. In spite of the use of the same technique, the difference in surgical outcomes among operating surgeons was not adequately reflected.
In conclusion, heart transplantation is a life-saving procedure for patients with end-stage heart failure with good early outcomes and relatively low catastrophic complications. Most of the early postoperative complications could be adequately managed with surgical or medical treatment and did not result in an extended hospital stay. We hope that this study can be used as a reference and can provide guidance for postoperative management after heart transplantation.
